AZN - AstraZeneca PLC
NASDAQ
->
Healthcare
->
Drug Manufacturers—General
Cambridge,
United Kingdom
Type: Equity
AZN price evolution
AZN
| (in millions $) | 31 Dec 2023 | 30 Sep 2023 | 30 Jun 2023 | 31 Mar 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $5840 | $4871 | $5664 | $6232 |
| Short term investments | $122 | $244 | $148 | $230 |
| Net receivables | $12929 | $12061 | $11844 | $10971 |
| Inventory | $5424 | $5292 | $5051 | $4967 |
| Total current assets | $25054 | $22501 | $22839 | $22266 |
| Long term investments | $1677 | $1290 | $1143 | $1234 |
| Property, plant & equipment | $10502 | $9700 | $9624 | $9599 |
| Goodwill & intangible assets | $58137 | $57626 | $58286 | $59292 |
| Total noncurrent assets | $76065 | $73585 | $73704 | $74421 |
| Total investments | $1799 | $1534 | $1291 | $1464 |
| Total assets | $101119 | $96086 | $96543 | $96687 |
| Current liabilities | ||||
| Accounts payable | $25034 | $22786 | $22136 | $22610 |
| Deferred revenue | ||||
| Short long term debt | $5400 | $5607 | $4787 | $3857 |
| Total current liabilities | $30542 | $28588 | $26375 | $24860 |
| Long term debt | $23222 | $22969 | $25051 | $27646 |
| Total noncurrent liabilities | $31411 | $30277 | $32752 | $36016 |
| Total debt | $28622 | $28576 | $29838 | $31503 |
| Total liabilities | $61953 | $58865 | $59127 | $60876 |
| Shareholders' equity | ||||
| Retained earnings | $1502 | -$434 | -$234 | -$1825 |
| Other shareholder equity | ||||
| Total shareholder equity | $39143 | $37197 | $37392 | $35789 |
| (in millions $) | 31 Dec 2023 | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $5840 | $1411 | $6329 | $7832 |
| Short term investments | $122 | $239 | $69 | $160 |
| Net receivables | $12929 | $11252 | $10539 | $7742 |
| Inventory | $5424 | $4699 | $8983 | $4024 |
| Total current assets | $25054 | $22593 | $26244 | $19544 |
| Long term investments | $1677 | $1142 | $1237 | $1147 |
| Property, plant & equipment | $10502 | $9449 | $10171 | $8917 |
| Goodwill & intangible assets | $58137 | $59127 | $62489 | $32792 |
| Total noncurrent assets | $76065 | $73890 | $79119 | $47185 |
| Total investments | $1799 | $1381 | $1306 | $1307 |
| Total assets | $101119 | $96483 | $105363 | $66729 |
| Current liabilities | ||||
| Accounts payable | $25034 | $19040 | $23871 | $21869 |
| Deferred revenue | ||||
| Short long term debt | $5400 | $5542 | $1893 | $2386 |
| Total current liabilities | $30542 | $26293 | $22594 | $20307 |
| Long term debt | $23222 | $23690 | $28888 | $17994 |
| Total noncurrent liabilities | $31411 | $33132 | $43482 | $30784 |
| Total debt | $28622 | $29232 | $30781 | $20380 |
| Total liabilities | $61953 | $59446 | $66076 | $51091 |
| Shareholders' equity | ||||
| Retained earnings | $1502 | $1495 | $1710 | $5299 |
| Other shareholder equity | $2040 | |||
| Total shareholder equity | $39143 | $37037 | $39268 | $15622 |
| (in millions $) | 31 Dec 2023 | 30 Sep 2023 | 30 Jun 2023 | 31 Mar 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $12024 | $11492 | $11416 | $10879 |
| Cost of revenue | $2308 | $2095 | $1960 | $1905 |
| Gross Profit | $9716 | $9397 | $9456 | $8974 |
| Operating activities | ||||
| Research & development | $3073 | $2584 | $2667 | $2611 |
| Selling, general & administrative | $5516 | $4929 | $5117 | $4193 |
| Total operating expenses | $8482 | $7443 | $7000 | $6425 |
| Operating income | $1234 | $1954 | $2456 | $2549 |
| Income from continuing operations | ||||
| EBIT | $1337 | $2040 | $2516 | $2626 |
| Income tax expense | -$62 | $274 | $268 | $458 |
| Interest expense | $439 | $392 | $430 | $365 |
| Net income | ||||
| Net income | $960 | $1374 | $1818 | $1803 |
| Income (for common shares) | $960 | $1374 | $1818 | $1803 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $45811 | $44351 | $37417 | $26617 |
| Cost of revenue | $8268 | $12391 | $12437 | $5299 |
| Gross Profit | $37543 | $31960 | $24980 | $21318 |
| Operating activities | ||||
| Research & development | $10935 | $9762 | $9736 | $5991 |
| Selling, general & administrative | $19755 | $18955 | $15234 | $11294 |
| Total operating expenses | $29350 | $28203 | $23924 | $16156 |
| Operating income | $8193 | $3757 | $1056 | $5162 |
| Income from continuing operations | ||||
| EBIT | $8519 | $3842 | $1035 | $5222 |
| Income tax expense | $938 | -$792 | -$380 | $772 |
| Interest expense | $1626 | $1346 | $1300 | $1306 |
| Net income | ||||
| Net income | $5955 | $3288 | $115 | $3144 |
| Income (for common shares) | $5955 | $3288 | $115 | $3144 |
| (in millions $) | 31 Dec 2023 | 30 Sep 2023 | 30 Jun 2023 | 31 Mar 2023 |
|---|---|---|---|---|
| Net income | $960 | $1374 | $1818 | $1803 |
| Operating activities | ||||
| Depreciation | $1327 | $1282 | $1276 | $1502 |
| Business acquisitions & disposals | -$296 | -$258 | -$184 | -$251 |
| Stock-based compensation | ||||
| Total cash flows from operations | $2380 | $3114 | $1718 | $3133 |
| Investing activities | ||||
| Capital expenditures | -$524 | -$314 | -$269 | -$122 |
| Investments | $109 | -$102 | $81 | $9 |
| Total cash flows from investing | -$1077 | -$1221 | -$520 | -$1246 |
| Financing activities | ||||
| Dividends paid | -$2 | -$1410 | -$22 | -$3047 |
| Sale and purchase of stock | $21 | $4 | $4 | $4 |
| Net borrowings | -$310 | -$1274 | -$1501 | $985 |
| Total cash flows from financing | -$291 | -$2726 | -$1519 | -$2031 |
| Effect of exchange rate | $6 | -$19 | -$36 | -$11 |
| Change in cash and equivalents | $1012 | -$833 | -$321 | -$144 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | $5955 | $3288 | $115 | $3144 |
| Operating activities | ||||
| Depreciation | $5387 | $5480 | $6530 | $3149 |
| Business acquisitions & disposals | -$989 | -$1061 | -$9413 | -$790 |
| Stock-based compensation | ||||
| Total cash flows from operations | $10345 | $9808 | $5963 | $4799 |
| Investing activities | ||||
| Capital expenditures | -$1229 | -$362 | -$1078 | -$855 |
| Investments | $97 | -$114 | $96 | $745 |
| Total cash flows from investing | -$4064 | -$2960 | -$11058 | -$285 |
| Financing activities | ||||
| Dividends paid | -$4481 | -$4364 | -$3856 | -$3572 |
| Sale and purchase of stock | $33 | $29 | $29 | $30 |
| Net borrowings | -$2100 | -$2361 | $7654 | $1440 |
| Total cash flows from financing | -$6567 | -$6823 | $3649 | -$2203 |
| Effect of exchange rate | -$60 | -$80 | -$62 | $12 |
| Change in cash and equivalents | -$286 | $25 | -$1446 | $2311 |
News
Fundamentals
| Market cap | $211.06B |
|---|---|
| Enterprise value | $233.84B |
| Shares outstanding | 3.08B |
| Revenue | $45.81B |
|---|---|
| EBITDA | $13.91B |
| EBIT | $8.52B |
| Net Income | $5.96B |
| Revenue Q/Q | 7.28% |
| Revenue Y/Y | 3.29% |
| P/E ratio | 35.44 |
|---|---|
| EV/Sales | 5.10 |
| EV/EBITDA | 16.82 |
| EV/EBIT | 27.45 |
| P/S ratio | 4.61 |
| P/B ratio | 5.39 |
| Book/Share | 12.71 |
| Cash/Share | 1.90 |
| EPS | $1.93 |
|---|---|
| ROA | 6.10% |
| ROE | 15.93% |
| Debt/Equity | 1.58 |
|---|---|
| Net debt/EBITDA | 4.04 |
| Current ratio | 0.82 |
| Quick ratio | 0.64 |